Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 427-434

  Minegaki, Tetsuya ^a   Takara, Kohji ^b   Hamaguchi, Ryohei ^a   Tsujimoto, Masayuki ^a   Nishiguchi, Kohshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b HIMEJI DOKKYO UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Cisplatin; Drug sensitivity; Esophageal carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GIMERACIL; GLUTATHIONE TRANSFERASE P1; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B2 PROTEIN; MENKES PROTEIN; MISMATCH REPAIR PROTEIN PMS2; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PROTEIN MLH1; PROTEIN MSH2; RAD51 PROTEIN; VERLUKAST; WILSON DISEASE PROTEIN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; DNA REPAIR; DRUG SENSITIVITY; ESOPHAGUS CARCINOMA; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84871531751     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1014     Document Type: Article

References (36)

1. National Cancer Center: Cancer statistics in Japan 2011. http://ganjoho.jp/public/statistics/backnumber/2011_jp.html. Accessed June 29, 2012.
2. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, Ogino T and Yoshida S: Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 35: 316-323, 2005.
3. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III and Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4: 855-863, 2005.
4. Kornmann M, Schwabe W, Sander S, Kron M, Sträter J, PolatS, Kettner E, Weiser HF, Baumann W, Schramm H, Häusler P, OttK, Behnke D, Staib L, Beger HG and Link KH: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9: 4116-4124, 2003.
5. Ciaparrone M, Quirino M, Schinzari G, Zannoni G, Corsi DC, Vecchio FM, Cassano A, La Torre G and Barone C: Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70: 366-377, 2006.
6. Larminat F and Bohr VA: Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 22: 3005-3010, 1994.
7. Andersson BS, Sadeghi T, Siciliano MJ, Legerski R and MurrayD: Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 38: 406-416, 1996.
8. Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, ChangCC, Tzeng CH, Wu KJ, Kao JY and Yang MH: Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res 16: 4561-4571, 2010.
9. Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T: Characterization of 21 newly established esophageal cancer cell lines. Cancer 69: 277-284, 1992.
10. Kitada N, Takara K, Minegaki T, Itoh C, Tsujimoto M, Sakaeda T and Yokoyama T: Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother Pharmacol 62: 577-584, 2008.
11. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T and Inui K: Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20: 379-386, 2005.
12. Filipski KK, Loos WJ, Verweij J and Sparreboom A: Interaction of Cisplatin with the human organic cation transporter 2. Clin Cancer Res 14: 3875-3880, 2008.
13. Karasawa H, Miura K, Fujibuchi W, Ishida K, Kaneko N, Kinouchi M, Okabe M, Ando T, Murata Y, Sasaki H, TakamiK, Yamamura A, Shibata C and Sasaki I: Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci 100: 903-913, 2009.
14. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, OhnishiN and Yokoyama T: Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 58: 785-793, 2006.
15. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, OsoegawaA, Shoji F and Maehara Y: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121: 895-900, 2007.
16. Noma B, Sasaki T, Fujimoto Y, Serikawa M, Kobayashi K, Inoue M, Itsuki H, Kamigaki M, Minami T and Chayama K: Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. Int J Oncol 33: 1187-1194, 2008.
17. Lan L, Hayashi T, Rabeya RM, Nakajima S, Kanno S, TakaoM, Matsunaga T, Yoshino M, Ichikawa M, Riele H, Tsuchiya S, Tanaka K and Yasui A: Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. DNA Repair (Amst) 3: 135-143, 2004.
18. Takizawa M, Kawakami K, Obata T, Matsumoto I, Ohta Y, OdaM, Sasaki T and Watanabe G: In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep 15: 1533-1539, 2006.
19. Pettersen HS, Visnes T, Vågbø CB, Svaasand EK, Doseth B, Slupphaug G, Kavli B and Krokan HE: UNG-initiated base excision repair is the major repair route for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA incorporation. Nucleic Acids Res 39: 8430-8444, 2011.
20. Li Y, Mizutani Y, Shiraishi T, Nakamura T, Mikami K, Takaha N, Okihara K, Kawauchi A, Sakai T and Miki T: The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer. BJU Int 99: 663-668, 2007.
21. Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, SugitoN, Mori R, Ogawa R, Katada T and Fujii Y: Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines. Dis Esophagus 21: 15-20, 2008.
22. Pedersen JM, Matsson P, Bergström CA, Norinder U, HoogstraateJ and Artursson P: Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 51: 3275-3287, 2008.
23. Reidling JC, Subramanian VS, Dahhan T, Sadat M and Said HM: Mechanisms and regulation of vitamin C uptake: studies of the hSVCT systems in human liver epithelial cells. Am J Physiol Gastrointest Liver Physiol 295: 1217-1227, 2008.
24. Nishimura M, Koeda A, Morikawa H, Satoh T, Narimatsu S and Naito S: Comparison of inducibility of multidrug resistance (MDR)1, multidrug resistance-associated protein (MRP)1, and MRP2 mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes. Biol Pharm Bull 31: 2068-2072, 2008.
25. Maubon N, Le Vee M, Fossati L, Audry M, Le Ferrec E, BolzeS and Fardel O: Analysis of drug transporter expression in human intestinal Caco-2 cells by real-time PCR. Fundam Clin Pharmacol 21: 659-663, 2007.
26. Dauchy S, Miller F, Couraud PO, Weaver RJ, Weksler B, RomeroIA, Scherrmann JM, De Waziers I and Declèves X: Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 77: 897-909, 2009.
27. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, ShimokataK, Takahashi T, Sekido Y and Yatabe Y: mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology 13: 510-517, 2008.
28. Sliwinski T, Krupa R, Majsterek I, Rykala J, KolacinskaA, Morawiec Z, Drzewoski J, Zadrozny M and Blasiak J: Polymorphisms of the BRCA2 and RAD51 genes in breast cancer. Breast Cancer Res Treat 94: 105-109, 2005.
29. Amirrad M, Al-Mulla F, Varadharaj G, John B, Saji T and AnimJT: BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters. Med Princ Pract 14: 67-72, 2005.
30. Müller A, Zielinski D, Friedrichs N, Oberschmid B, Merkelbach-Bruse S, Schackert HK, Linnebacher M, vonKnebelDoeberitz M, Büttner R and Rüschoff J: Reduced mRNA expression in paraffin-embedded tissue identifies MLH1-and MSH2-deficient colorectal tumours and potential mutation carriers. Virchows Arch 453: 9-16, 2008.
31. Veeriah S, Kautenburger T, Habermann N, Sauer J, DietrichH, Will F and Pool-Zobel BL: Apple flavonoids inhibit growth of HT29 human colon cancer cells and modulate expression of genes involved in the biotransformation of xenobiotics. Mol Carcinog 45: 164-174, 2006.
32. Uthus EO, Reeves PG and Saari JT: Copper deficiency decreases plasma homocysteine in rats. J Nutr 137: 1370-1374, 2007.
33. Hoang YD, Avakian AP and Luderer U: Minimal ovarian upregulation of glutamate cysteine ligase expression in response to suppression of glutathione by buthionine sulfoximine. Reprod Toxicol 21: 186-196, 2006.
34. Gustavsson B, Kaiser C, Carlsson G, Wettergren Y, Odin E, Lindskog EB, Niyikiza C and Ma D: Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. Int J Cancer 124: 1220-1226, 2009.
35. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, Kitajima M, Takechi T and Fukushima M: Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94: 633-638, 2003.
36. Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T and Shirao K: Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98: 832-839, 2008.